Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (7150)	4/19/2001 5:32:05 PM
From: shakedown	Read Replies (1) \| Respond to of 14101

You beat me. (eom)

To: Montana Wildhack who wrote (7150)	4/19/2001 10:56:21 PM
From: David Graham	Read Replies (1) \| Respond to of 14101

My attempt to figure out how much DMX got from Provalis; Dimethaid cash at the beginning of the quarter: $2,238 Loss for the quarter $-3,499 (9-month loss of 7,597 less 6-month loss of 4,098) Plus depreciation $ 200 Plus Financing proceeds $2,618 Projected quarter end cash of: $1,557 Reported quarter end cash of: $2,968 Excess cash: $1,402 This is based on the scantiest of info provided in the quarterly news releases. However, I was able to do a decent job of reconciling the prior two quarters. Another thing. In the second quarter, DMX stated that they had stockpiled $700K worth of Pennsaid, there was no mention of the inventory level at the end of Q3. For example, if they had produced another $500K worth in the third quarter, that would have represented a use of cash that wasn’t expensed. In English, that means that the ‘Excess cash’ line above would be higher by the amount spent on producing Pennsaid during the quarter. Based on my math (and I’m pretty tired right now, so it could be suspect), there is an extra $1.4 million or so in the till. The answer probably can’t be this straightforward, so please help me out contribute anything to this analysis.